2011 Scrip 100: Land grab for CROs
This article was originally published in Scrip
As relationships between pharma companies and service providers become more strategic, a handful of innovative new outsourcing models are starting to grain traction. Joanne Payne and Jonathan Hare examine how the changing expectations of trial sponsors are affecting the way CROs win new business.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"